Navigation Links
Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer

ASCO Oral Presentation Reports Significantly More Patients Treated with Taxotere(R)-Based Chemotherapy Regimen Survived at Least Three Years

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Taxotere(R) (docetaxel) Injection Concentrate-based chemotherapy (Taxotere plus prednisone) maintained long-term efficacy as a treatment for advanced (metastatic) hormone-resistant prostate cancer patients, according to the three-year updated results of the landmark TAX 327 study. Results of the international multi-center phase III trial were reported in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The TAX 327 data show that among patients with metastatic hormone- resistant prostate cancer, significantly more of those treated with Taxotere(R) 75mg/m2 combined with prednisone 5 mg once every three weeks survived at least three years, than those treated with anti-cancer antibiotic mitoxantrone combined with prednisone. Patients treated with the Taxotere(R) regimen lived a median of three months longer (19.3 months versus 16.3 months, p=0.006) and had a 21% lower risk of dying (HR=17.6-21.3). These results are consistent with results published in 2004 in the New England Journal of Medicine and document the maintenance of the survival benefit previously reported in patients treated with the Taxotere-based therapy.

"The results confirm docetaxel's survival benefit in patients with metastatic hormone resistant prostate cancer," said study author Dominik R. Berthold, Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada. "Prolonged survival is extremely important for these patients and docetaxel is the only chemotherapeutic agent to demonstrate a survival benefit in this setting."

Original TAX 327 Analysis Showed Improved Survival

The TAX 327 study was initiated in 2000 to evaluate long-term survival among men with metastatic h
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger ... most of the world. As an engineer for the past 20 ... member of the military service. He,s been to six of the ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... for travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... at a rate of 4%, with world market ... Kalorama Information. MRI and other types of medical ... and treatment of numerous medical conditions in children ... and techniques. Kalorama,s report, Medical Imaging Markets ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... , , SEATTLE, Dec. 9 Omeros Corporation today ... to serve on the Company,s Board. Mr. Spiegelman has also been ... are very pleased to welcome Dan to our Board and look ... CEO of Omeros. "Dan brings a substantial depth and breadth of ...
... , WALTHAM, Mass., Dec. 9 Decision ... focusing on pharmaceutical and healthcare issues, finds that compared to ... are being used more often to treat newly diagnosed patients ... second-line patients received a TNF-alpha inhibitor versus one year ago ...
Cached Medicine Technology:Daniel K. Spiegelman Elected to Board of Directors of Omeros 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3
(Date:11/28/2014)... Recently, BellasDress , a renowned dress manufacturer in the ... of cocktail dresses. In addition, these fresh dresses are available ... shipping on orders over $179. The aim of the special ... providing many styles of dresses, which come in various colors; ... more. All of them are on sale at affordable prices. ...
(Date:11/28/2014)... November 29, 2014 Recently, SWAccessControl.com, a ... systems. At the moment, all these high end products ... off. The special offer will last from today to ... “We are happy to launch the promotion. We are ... worldwide distributors with the latest information about our hottest ...
(Date:11/28/2014)... Recently, PrettyTailor.com has developed and created its new collection ... world in celebration of the coming holiday season. To ... special offer on all these outfits. Click here ... the garment industry, PrettyTailor.com brings together art and technology ... The business carries quite a few in eye-catching patterns ...
(Date:11/28/2014)... The month of December has the highest ... occurring in Florida every year in December , attorney Sean ... insurance policies. , "Optional auto insurance coverage is something you ... cheap I know, actually Florida is among the states, where ... but what I see is that the insurance required by ...
(Date:11/28/2014)... News) -- People with diabetes face a number of challenges ... healthy, an expert says. "With the holidays coming, take ... events, the family you,ll be visiting and all of the ... Educators, said in an association news release. "By planning ahead. ... One idea is to make a healthy eating contract with ...
Breaking Medicine News(10 mins):Health News:BellasDress Offers A Big Surprise By Updating Its Cheap and Charming Cocktail Dresses 2Health News:New Access Control Systems Now Offered At Low Prices By Smartware Manufacturer SWAccessControl.com 2Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Car Accident Attorney Sean M. Cleary on Auto Insurance Policies Essential for Florida Drivers 2Health News:Holiday Eating Tips for People With Diabetes 2
... sedimentation rate (ESR) increases during pregnancy. Also, both ... ,The erythrocyte sedimentation rate is one of ... is helpful in detecting the presence of inflammation ... by anaemia, which may be present in inflammatory ...
... to be in critical condition in a hospital here where ... government said. // ,Narayanan, who turned 85 ... and Referral Hospital two days later and has been on ... his condition. He continues to be critical, the aide said. ...
... are now produced which has been found to have ... Immunotherapy vaccines. //Antibodies against the allergen is given as ... allergen or infection these antibodies which are already present ... ,Conventional antibody injections against allergy diseases such ...
... the November issue of the Journal of the National Cancer ... after treatment, and patients treated with the higher chemotherapy dose ... ,Germ-cell testicular cancer is the most common cancer among 20-40 ... an age at which they are starting a family, and ...
... is a FDA approved long-term treatment regime for patients ... therapy is now being offered to patients at NewYork-Presbyterian ... now the first treatment specifically approved for TRD in ... therapy has been unsuccessful atleast in four or more ...
... cancer does not mean that you can cool your heels, ... experts have warned people. // ,These warnings were ... by eminent doctors who took part in a panel discussion ... In a keynote address delivered on the occasion, Prof D ...
Cached Medicine News:Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The patented ... provides a long shelf life that ...
... Infinity Creatinine single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Creatinine reagent provides a long shelf ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
Medicine Products: